The functional interaction between abaecin and pore-forming peptides indicates a general mechanism of antibacterial potentiation  by Rahnamaeian, Mohammad et al.
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a  b  s  t  r  a  c  t
Long-chain  proline-rich  antimicrobial  peptides  such  as bumblebee  abaecin  show  minimal  activity  against
Gram-negative  bacteria  despite  binding  efﬁciently  to speciﬁc  intracellular  targets.  We  recently  reported
that bumblebee  abaecin  interacts  with  Escherichia  coli DnaK  but shows  negligible antibacterial  activ-
ity  unless  it  is  combined  with  sublethal  doses  of  the pore-forming  peptide  hymenoptaecin.  These  two
bumblebee  peptides  are  co-expressed  in  vivo  in  response  to a  bacterial  challenge.  Here  we investi-
gated  whether  abaecin  interacts  similarly  with  pore-forming  peptides  from  other  organisms  by  replacing
hymenoptaecin  with  sublethal  concentrations  of  cecropin  A  (0.3  M)  or stomoxyn  (0.05  M).  We  found
that  abaecin  increased  the  membrane  permeabilization  effects  of  both  peptides,  conﬁrming  that  it can
reduce  the  minimal  inhibitory  concentrations  of pore-forming  peptides  from  other  species.  We  also  used
atomic  force  microscopy  to show  that 20 M abaecin  combined  with  sublethal  concentrations  of  cecropintomic force microscopy
-galactosidase assay
A  or  stomoxyn  causes  profound  structural  changes  to  the  bacterial  cell surface.  Our data  indicate  that
the  potentiating  functional  interaction  between  abaecin  and  pore-forming  peptides  is  not  restricted  to
speciﬁc  co-expressed  peptides  from  the  same  species  but is likely  to  be  a general  mechanism.  Combina-
tion  therapies  based  on  diverse  insect-derived  peptides  could  therefore  be  used  to tackle  bacteria  that
are recalcitrant  to  current  antibiotics.
© 2016  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
The insect innate immune system comprises a complex series of
ellular and molecular defense strategies that recognize and com-
at pathogens [20,31]. Comparative genomics and transcriptomics
as revealed remarkable levels of evolutionary plasticity among
he components, which allows insects to respond more rapidly to
athogens with smaller genomes and shorter life cycles, and thus
 greater capacity for evolutionary adaptation [5,6,31]. One partic-
larly adaptable component of the insect immune system is the
pectrum of antimicrobial peptides (AMPs) that can be deployed,
 diversiﬁcation process driven by gene duplication, exon duplica-
ion and exon shufﬂing [30]. Larger repertoires of AMPs not only
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target different pathogens through speciﬁc interactions, but also
allow functional interactions among different AMPs, such as poten-
tiation and synergism [21]. This can extend the range and speciﬁcity
of responses and can also boost the efﬁcacy of AMPs at low concen-
trations, which helps to conserve resources and reduce the trade-off
between immunity and other functions [27].
We recently reported that functionally-distinct insect AMPs
expressed concurrently during an immune response can recipro-
cally potentiate each other’s activities [21]. Similar phenomena
have been reported in other contexts [9,11,28,36,37]. However,
such interactions have not been studied in detail and the evaluation
of AMPs in terms of potency against different pathogens is almost
universally achieved using individual peptides, which is likely to
underestimate their therapeutic potential.
Long-chain (>20 residues) proline-rich antimicrobial peptides
were originally believed to be active solely against Gram-positive
bacteria and fungi [19,22,23]. We  recently found that bumble-
bee abaecin is also inactive against Gram-negative bacteria such
as Escherichia coli at higher concentrations [21]. Interestingly, we
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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lso found that much lower concentrations of abaecin were lethal
o E. coli in the presence of the pore-forming peptide hymenop-
aecin, another bumblebee AMP  which is co-expressed in vivo
ith abaecin [26]. We  observed evidence for reciprocal potenti-
tion between these AMPs, i.e. hymenoptaecin created membrane
ores that allowed abaecin access to its intracellular target (DnaK)
nd abaecin inhibited protein metabolism and prevented the bac-
eria from repairing the pores, thus reducing the minimal inhibitory
oncentration (MIC) of both components [21].
Although this earlier study provided clear evidence for poten-
iating interactions among AMPs, both peptides are co-expressed
aturally in response to bacterial challenge so it remained unclear
hether this was a speciﬁc mechanism or an example of a more
eneral phenomenon. Here we describe further experiments in
hich abaecin is combined with pore-forming peptides from two
eterologous species. We  used a -galactosidase assay to deter-
ine the permeability of the bacterial membrane in the presence
f different combinations and quantities of each AMP, and atomic
orce microscopy (AFM) to investigate the impact of different AMP
ombinations on the structure of the bacterial cell surface. The abil-
ty to combine functionally compatible AMPs from different insect
pecies could expand the spectrum of pathogens that can be tar-
eted with peptide antibiotics and could usher in a new era of
ombinatorial microbicides.
. Materials and methods
.1. Peptide synthesis and modiﬁcation
Abaecin (Bombus pascuorum), cecropin A (Hyalophora cecropia)
nd stomoxyn (Stomoxys calcitrans) peptides were synthesized
y PANATecs (Tübingen, Germany) with >95% purity and the C-
ermini of cecropin A and stomoxyn were amidated. The amino
cid sequences of the three peptides are shown in Table 1.
.2. Growth inhibition assays
Growth inhibition assays in 384-well plates (Griener Bio One,
rickenhausen, Germany) were carried out using E. coli strain D31
n lysogeny broth (starting OD600 = 0.001). The AMPs were added
s serial dilutions from 250 to 0.03 M (ﬁnal concentrations).
he OD600 was measured over 16 h with a reading every 20 min
n an EonTM Microplate Spectrophotometer (BioTek Instruments,
inooski, VT, USA). Control cultures with no AMPs were included
n the assays.
.3. Permeabilization assays
The permeabilization activities of the AMPs were determined
y measuring -galactosidase activity in E. coli strain JM83. This
ontains the plasmid pCH110 (Pharmacia-Amersham, Piscatway,
J, USA), which confers ampicillin resistance and the constitutive
ynthesis of cytoplasmic -galactosidase [37]. The AMPs were pre-
ncubated for 15 min  at 37 ◦C in 23 l 20 mM phosphate buffer
pH 6.8) before adding 2 l of the mid-logarithmic phase bac-
erial cell suspension (5 × 105 colony forming units) prepared in
he same buffer. The samples were incubated at 37 ◦C for 45 min
efore adding 220 l 20 mM HEPES/150 mM NaCl (pH 7.5) and 5 l
0 mM aqueous p-nitrophenyl--d-galactopyranoside. After incu-
ation for 90 min  at 37 ◦C, the absorbance was measured at 405 nm
n Benchmark PlusTM Microplate Spectrophotometer (BioRad Labo-
atories, Hercules, CA, USA). Samples containing bacteria incubated
ithout AMPs were used as negative controls and samples of bacte-
ia killed with 5 M synthetic cecropin B (Sigma–Aldrich, St. Louis,
O,  USA) were used as positive controls. The permeabilization
ndex was calculated by correcting for the negative control at 0%ides 78 (2016) 17–23
and setting the positive control to 100%. All assays were carried out
three times in triplicate. Statistical analysis was carried out using
Student’s t-test with the following signiﬁcance values: *p < 0.05;
**p ≤ 0.01; ***p ≤ 0.001.
2.4. Atomic force microscopy
Samples for AFM were prepared as previously described [36,37].
Log-phase E. coli JM83 cells in 100 l lysogeny broth (OD600 = 0.2)
were incubated in the presence of AMPs (or without AMPs as
a negative control) at 37 ◦C for 90 min. The ﬁnal concentra-
tions of abaecin, cecropin A, and stomoxyn were 20 M,  0.3 M
and 0.05 M,  respectively. The bacteria were then centrifuged
(8000 × g, 10 min, 4 ◦C), washed twice with apyrogenic water, sus-
pended in 5 l of apyrogenic water, applied to mica disks and dried
overnight at 28 ◦C before analysis.
Cell surface imaging and analysis were carried out using a
NanoScope V AFM (Veeco Instruments, Plainview, NY, USA) in Peak
Force QNM operation mode, ﬁtted with a silicon tip NSG 30 with
a spring constant of 20 N/m (NT-MDT, Moscow, Russian Federa-
tion). Three ﬁelds were imaged for each sample. Data were analyzed
using Nanoscope Analysis v1.40 (Veeco Instruments). The aver-
age surface root mean square (RMS) roughness was  calculated
from 25 ﬁelds (300 nm × 300 nm)  measured over the entire cell
surface in 3 m × 3 m areas. WSxM v5.0 software was used to
produce 3D images and section proﬁles. Statistical differences in
RMS roughness were determined by analysis of variance (ANOVA)
using Fisher’s least signiﬁcant difference (LSD) test.
2.5. Analysis of hydropathy
The hydropathy of the pore-forming AMPs was  determined
using ProtScale [14] on the ExPASy server (http://web.expasy.org/
protscale/).
3. Results
3.1. Potency of the AMPs in bacterial growth inhibition assays
E. coli strain D31 showed no susceptibility in the presence of
up to 200 M abaecin and entered the exponential growth phase
∼4 h after the initiation of cultivation (data not shown). In contrast,
cecropin A and stomoxyn exhibited potent bactericidal activities at
concentrations of 1 and 0.1 M,  respectively. The sublethal concen-
trations of the AMPs were determined by preparing serial dilutions
and repeating the growth inhibition assays. This revealed that
cecropin A and stomoxyn had sublethal concentrations of 0.3 and
0.05 M,  respectively (data not shown). Combinatorial assays were
carried out by supplementing the sublethal doses of each pore-
forming peptide with 20 M abaecin (Fig. 1).
3.2. Permeabilization of the bacterial cell membrane
To determine whether the lethal effect of the combined peptides
was due to the increase in the permeabilization of the bacte-
rial membrane, we used the standard bacterial strain E. coli JM83
which constitutively expresses cytoplasmic -galactosidase. Both
cecropin A and stomoxyn caused near maximum permeabilization
of the bacterial membrane at a concentration of 2.5 M (Fig. 2). The
administration of sublethal concentrations of each peptide indi-
vidually had no effect on membrane permeability, but when each
was supplemented with 20 M abaecin (which alone increased
permeability by only ∼ 5%), the permeabilization of the bacterial
membrane increased signiﬁcantly. The presence of 0.3 M cecropin
A and 0.05 M stomoxyn increased membrane permeability caused
by 20 M abaecin by 7-fold and 2-fold, respectively (Fig. 2). These
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Table  1
Amino acid sequences of AMPs used in this study. The C-terminus of cecropin A and stomoxyn was modiﬁed by amidation.
Peptide Origin Sequence Reference
Abaecin Bombus pascuorum FVPYNPPRPGQSKPFPSFPGHGPFNPKIQWPYPLPNPGH [25]
Cecropin A Hyalophora cecropia KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH 2 [29]
Stomoxyn Stomoxys calcitrans RGFRKHFNKLVKKVKHTISETAHVAKDTAVIAGSGAAVVAAT-NH 2 [4]
Fig. 1. Escherichia coli growth inhibition assays. (a) E. coli strain D31 in mid-
logarithmic phase was  incubated with medium (control) or with abaecin and
stomoxyn, alone or in combination. (b) E. coli strain D31 in mid-logarithmic phase
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Fig. 2. Membrane permeabilization assay in E. coli JM83 cells. The graphs show
the  activities of abaecin (Aba), cecropin A (Cec) and stomoxyn (Sto) against the
bacterial cell envelope determined by measuring activity of -galactosidase. Cells in
mid-logarithmic phase were treated with peptides alone or in combination, and the
absorbance at 405 nm was  proportional to the amount of the substrate converted by
the  -galactosidase. Living bacteria incubated with no AMPs were used as a negative
control and bacteria killed by treatment with 5 M synthetic cecropin B were usedas  incubated with medium (control) or with abaecin and cecropin A, alone or in
ombination. The growth rate was determined by measuring the optical density
OD) of the culture at 600 nm.
esults clearly show that the two heterologous pore-forming pep-
ides potentiate the activity of the long-chain proline-rich peptide
baecin in E. coli, even though they have no pore-forming ability
hen applied individually at their sublethal concentrations. The
ermeabilization assay results clearly correlated with the results
f growth inhibition assay (Fig. 1).
.3. Impact of AMPs on the structure of the bacterial cell surface
The exposure of E. coli to individual AMPs or combinations
hereof resulted in structural alterations to the bacterial cell
urface. AFM imaging of untreated bacteria revealed regular rod-
haped cells, with numerous ﬂagella and a cell surface covered in
mall granules and irregular ﬂat grooves (Fig. 3). Exposure to 20 M
baecin resulted in cells that appeared smoother than untreated
ontrols, with less pronounced granules and grooves (Fig. 3). The
hanges were also observed in sectional proﬁles (Fig. 4). These data
onﬁrm our previous results [21,36]. Although cells incubated withas  a positive control. Values represent means ± SD (n = 3). Statistical signiﬁcance
versus control: **p ≤ 0.01, ***p ≤ 0.001.
0.3 M cecropin A retained their shape and ﬂagella, they devel-
oped an additional ﬂattened envelope. The topography of the cell
surface also changed: the superﬁcial granules became less sharply
deﬁned and more ovoid in morphology (Fig. 3) and new cavities
appeared on the surface, 15–20 nm deep and 100–150 nm in diam-
eter (Fig. 4). In contrast, the cells incubated with 0.05 M stomoxyn
underwent much more severe changes in morphology, losing their
regular shape and envelope and developing larger cavities than the
cells exposed to cecropin A, i.e. circular or longitudinal in proﬁle, up
to 40 nm deep and 150–200 nm wide (Fig. 4). The cell surface also
became partially covered with patches of unidentiﬁed material,
probably originating from the damaged cell envelope (Fig. 3).
The exposure of bacteria to the combinations of AMPs led to
a distinct set of surface alterations compared to bacteria treated
with individual peptides, but the precise nature of these alter-
ations differed according to the mixture of AMPs applied (Figs.
3 and 4). In the cultures treated with 20 M abaecin and 0.3 M
cecropin A, there was  a substantial loss of surface granularity and
the surface instead became covered in ﬂat furrows, 2–4 nm deep
and 50–80 nm wide (Fig. 4). These cells were also surrounded by a
damaged, jagged and uneven cell envelope. In contrast, the bacte-
ria treated with 20 M abaecin and 0.05 M stomoxyn developed a
20 M. Rahnamaeian et al. / Peptides 78 (2016) 17–23
Fig. 3. Gross morphology of E. coli JM83 cells treated with 20 M abaecin, 0.3 M cecropin A, and 0.05 M stomoxyn, alone or in combination. The control cells were incubated
without AMPs. Scale bars in each left panel refer to the entire row.
Table 2
The effect of AMPs on the roughness of E. coli JM83 cells.
Control Cecropin A (0.3 M) Stomoxyn (0.05 M)  Abaecin (20 M) Cecropin A + Abaecin Stomoxyn + Abaecin
00a (±
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tRoughness RMS  value (nm) ± SD 5.983b (±1.81) 7.369c (±2.149) 9.7
tatistical signiﬁcance between treatments: p < 0.05 (ANOVA; Fisher’s LSD test). Val
ore uneven surface, with irregular recesses and furrows 5–10 nm
eep and 50–100 nm wide (Fig. 4). These substantial changes in
urface topography were accompanied by signiﬁcant differences
n the cell surface RMS  roughness compared to untreated controls,
ith the exception of cells treated with abaecin alone (Table 2).
. Discussion
We  have previously shown that bumblebee abaecin alone does
ot affect bacterial proliferation at concentrations of up to 200 M
nd has negligible membrane permeabilization activity (∼5%) at
oncentrations of up to 20 M,  but can potentiate activity of
ymenoptaecin (a pore-forming peptide also from the bumblebee)
nd thus reduce the MIC  of hymenoptaecin required for membrane
ermeabilization [21]. This interaction could be speciﬁc, given that
he two AMPs are naturally co-expressed in response to a bacte-4.031) 5.558b (±2.423) 7.214c (±3.001) 7.318c (±1.625)
arked with the same letter are not signiﬁcantly different.
rial challenge, but could also represent a more general mechanism.
We therefore tested the activity of abaecin with two other pore-
forming AMPs: H. cecropia cecropin A and S. calcitrans stomoxyn
[8,15]. Both are -helical cysteine-free peptides, whereas abaecin
is a proline-rich peptide [15,25].
We found that E. coli strain D31 showed no evidence of growth
inhibition in the presence of up to 200 M abaecin, in agreement
with our previous studies [21]. In contrast, Rees et al. observed sig-
niﬁcant growth inhibition, although they used an abaecin fraction
prepared by HPLC [25] and the precise concentration was  not deter-
mined, so it is possible they applied a much higher concentration
than we used in our experiments. They also used a different bac-
terial strain (E. coli strain D22) which has a membrane defect that
might pre-dispose the bacteria to membrane permeabilization.
Stomoxyn and cecropin A have similar structures and their
mechanisms of action are therefore related. Stomoxyn adopts a typ-
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oig. 4. Surface proﬁles of E. coli JM83 cells treated with 20 M abaecin, 0.3 M cecro
ithout  AMPs. In each panel, (a) shows height images of the bacterial cell surface a
cal cecropin structure, including cationic N-terminal amphipathic
nd C-terminal hydrophobic -helices, but the C-terminal helix of
tomoxyn is not well deﬁned. Both peptides are thought to form
ransmembrane pores via a “carpet-like” mechanism [15]. These
eptides must interact with outer membrane components initially
n order to reach the inner membrane of Gram-negative bacteria,
hich is the target for most cationic defense peptides. The cationic
eptides are likely to bind negatively-charged lipopolysaccharides
hus displacing the divalent ions that stabilize the outer membrane
tructure [7,10,34].
Our AFM data revealed that the application of each AMP  indi-
idually in sublethal concentrations caused a unique spectrum of
tructural changes on the bacterial cell surface, reﬂecting the ini-
ial interactions described above (Figs. 3 and 4). The structural
ifferences are likely to reﬂect the different properties and/or
onformations of each peptide, which determine the envelope com-
onents with which they interact, the binding afﬁnity and the
mpact on normal envelope functions. Even so, none of the inter-
ctions appeared to be detrimental because bacterial growth and
roliferation were unaffected (Fig. 1).Whereas sublethal concentrations of each individual AMP  had
o effect on bacterial growth, combinations of abaecin and each
f the two pore-forming peptides resulted in profound changes, and 0.05 M stomoxyn, alone or in combination. The control cells were incubated
 shows section proﬁles corresponding to the lines marked in (a).
to the cell surface (Figs. 3 and 4) as well as an absolute inhi-
bition of bacterial proliferation (Fig. 1) suggesting that abaecin
reduces the MIC  of the other AMPs as previously observed for
bumblebee hymenoptaecin [21]. The increase in permeabilization
caused by the combined AMPs was quantiﬁed by measuring the
-galactosidase activity (Fig. 2) and was eventually lethal to the
cells. Both heterologous peptides were therefore potentiated by
abaecin in a similar way  to hymenoptaecin. As a result, in the
presence of sublethal concentrations of these pore-forming pep-
tides, 20 M abaecin was sufﬁcient to inhibit bacterial growth and
proliferation (Fig. 1). Considering the concentrations, stomoxyn is
more potent than cecropin A in terms of potentiating the effect
of abaecin, but both are more potent than hymenoptaecin [21].
Based on its structural characteristics, stomoxyn functions like
cecropin A by disrupting bacterial membranes [15]. The differences
in antimicrobial potency may  also reﬂect their hydrophobicity:
hydropathy plots (Fig. 5) show that the C-terminal -helices of
cecropin A and stomoxyn are much more hydrophobic than the
short, scattered hydrophobic regions in glycine-rich hymenop-
taecin, increasing their afﬁnity for the bacterial membrane. This is
also supported by the grand average hydropathicity (GRAVY) scores
of hymenoptaecin (−0.859), cecropin A (−0.073) and stomoxyn
(−0.002). Although hymenoptaecin is not as potent as stomoxyn
22 M. Rahnamaeian et al. / Pept
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ydrophobic and hydrophilic domains are shown above and below zero, respec-
ively. The size of the window is nine residues.
nd cecropin A in terms of membrane permeabilization, it never-
heless fulﬁls this role in the bumblebee [21]. The AMP  potentiation
echanism is likely to be based on reciprocal functional augmen-
ation: the pore-forming peptides facilitate the uptake of abaecin
hich then binds to DnaK and inhibits its chaperone activity; this
n turn accelerates the loss of membrane integrity by interrupt-
ng repair processes [21]. Similar phenomena have been observed
ith other combinations of peptides, such as LL-37 and human
-defensin [3,12,16,17,18,33,35].
Our data suggest that potentiating functional interactions
etween abaecin and pore-forming peptides are not restricted
o AMPs produced in the same species and are likely to rep-
esent a more general mechanism that works across species
arriers. Combinations of AMPs from different species could there-
ore be tested to determine whether this increases their potency
nd/or the range of pathogens that become susceptible, as already
[
[ides 78 (2016) 17–23
reported for cecropin + mellitin [1], attacin + thanatin [32] and
cecropin + thanatin [13]. Such strategies may  be used in future com-
bination antimicrobial therapy, to confer pathogen resistance in
transgenic plants [2], or to develop cosmetic products that deter
dermatological pathogens [24].
5. Conclusions
The bumblebee long-chain proline-rich peptide abaecin can
potentiate the activity of pore-forming AMPs from other species,
in this case cecropin A and stomoxyn. This potentiating functional
interaction represents a promising therapeutic scenario because
the potency and range of combinations of AMPs is likely to extend
well beyond the capabilities of individual peptides. In addition
to combination therapy, individual synthetic peptides could be
designed containing the active sequences of two or more natural
AMPs, which could then be used for comprehensive clinical testing
against diverse range of bacteria. This provides a real opportunity
to address the rising threat of multidrug resistant pathogens that
are recalcitrant to conventional antibiotics.
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